K. Kerrou

Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial

Bruno Coudert, Jean‐Yves Pierga, Marie‐Ange Mouret‐Reynier et al. · The Lancet Oncology · 2014 · 139 citations

Breast Oncology, Medicine, Neoadjuvant Trastuzumab +8

Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma

Laurence Moureau-Zabotto, E. Touboul, D. Lerouge et al. · International Journal of Radiation Oncology*Biology*Physics · 2005 · 132 citations

Positron Emission Tomography, Esophageal Cancer, Medical Imaging +9

Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non–small-cell lung cancer

Élisabeth Deniaud-Alexandre, E. Touboul, D. Lerouge et al. · International Journal of Radiation Oncology*Biology*Physics · 2005 · 121 citations

Computed Tomography, Non–small-cell Lung Cancer, Oncologic Imaging +12

Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study

Bruno Coudert, Jean‐Yves Pierga, Marie‐Ange Mouret‐Reynier et al. · EClinicalMedicine · 2020 · 10 citations · Full text